FDA approves Eisai and Biogen's subcutaneous Leqembi

The FDA approved a new formulation of Eisai and Biogen’s Alzheimer’s drug Leqembi, an incremental step in the companies’ strategy to compete with Eli Lilly’s Kisunla. The new formulation can be injected under the skin ...